With an estimated 400 million people at risk for developing dementia, a natural remedy would be a welcome answer. That's the approach one British company is taking.
Nanonucleant, a spin-out of Imperial College London, is seeking angel financing to move ahead with a glass grain-based technology that aids in crystallising proteins for study as drug targets.
A microchip that mimics the function of the human brain could one day result in a mobile phone with the memory capacity of a desktop computer, researchers report.
Imperial College London's technology commercialisation company is betting on a spin-out company, deltaDOT, to speed detection and decrease costs of finding new proteins for drug discovery.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.